Real world study of trastuzumab (Zercepac)

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2200059543

Enrollment

Unknown

Registered

2022-05-04

Start date

2022-07-01

Completion date

Unknown

Last updated

2024-03-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

breast cancer

Interventions

Experimental group:Zercepac

Eligibility

Sex/Gender

Female

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: HER2 positive breast cancer patients.

Exclusion criteria

Exclusion criteria: 1. Refused to be included in this study or to cooperate with follow-up; 2. Patients who participated in other intervention studies within 4 weeks.

Design outcomes

Primary

Measure	Time frame
progress-free survival;	—

Secondary

Measure	Time frame
overall survival;	—

Countries

China

Contacts

Public ContactFeng Jifeng

Jiangsu Province Cancer Hospital

fjif@medmail.com.cn+86 25 83283318

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026